US healthcare giant Johnson & Johnson is to buy Actelion, Europe's biggest biotech company – paying $30 billion (28 billion euros).
The purchase gives Johnson & Johnson access to the Swiss group's highly profitable range of medicines for rare diseases.
The deal represents a 23 percent premium to Actelion's closing price on Wednesday and is more than 80 percent above the November 23 closing price before takeover reports first emerged.
